A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma

Surwit, R. S.

doi:10.1001/archderm.120.3.329

Cited by 15 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These trials showed a reduction in the number and severity of RP episodes in patients treated with the active medications. However, these 2 studies, as well as other trials evaluating calciumchannel blockers, ␣-adrenergic inhibitors, and selective serotonin reuptake inhibitors, did not use the RCS, a now accepted and valid measure of severity of RP (5,11,(16)(17)(18)(19)(20). In addition, most previous studies used paper diaries rather than electronic diaries that prompted patients to input their daily RCS.…”

Section: Discussionmentioning

confidence: 99%

MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial

Chung¹,

Shapiro²,

Fiorentino³

et al. 2009

Arthritis & Rheumatism

105

View full text Add to dashboard Cite

Objective. Raynaud's phenomenon (RP) affects 3-9% of the general population and >90% of patients with systemic sclerosis. Nitrates are often prescribed for the treatment of RP, but currently available formulations are limited by side effects, particularly headaches, dizziness, and skin irritation. The purpose of this study was to evaluate the tolerability and efficacy of a novel formulation of topical nitroglycerin, MQX-503, in the treatment of RP in an ambulatory setting.Methods. We conducted a multicenter, randomized, placebo-controlled study with a 2-week single-blind run-in period to determine baseline severity, followed by a 4-week double-blind treatment phase. Two hundred nineteen adult patients with a clinical diagnosis of primary or secondary RP received 0.9% MQX-503 gel or matching placebo during the treatment period. Gel was applied immediately before or within 5 minutes of the beginning of an episode of RP (maximum of 4 applications daily). End points included the change in the mean Raynaud's Condition Score (RCS; scale 0-10), the frequency and duration of episodes, and subjective assessments at the target week (the week during the treatment phase that most closely matched the run-in period in terms of ambient temperature) compared with baseline.Results. The mean (%) change in the RCS at the target week compared with baseline was significantly ClinicalTrials.gov identifier: NCT00419419.

show abstract

Section: Discussionmentioning

confidence: 99%

MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial

Chung¹,

Shapiro²,

Fiorentino³

et al. 2009

Arthritis & Rheumatism

105

View full text Add to dashboard Cite

show abstract

“…These have included either exclusively SSc-related RP patients [66] or patients with both PRP and SRP (including SSc-related RP) [67]. These were both randomized, double-blind, crossover studies, the longest duration (per treatment arm) being 8 weeks [66]. In PRP and SRP (not SSc-related), prazosin was more effective than placebo in reducing the frequency and severity of RP attacks [67].…”

Section: Sympatholytic Drugs 4421 A-1 Adrenergic Receptor Antagonistsmentioning

confidence: 99%

“…In PRP and SRP (not SSc-related), prazosin was more effective than placebo in reducing the frequency and severity of RP attacks [67]. However, in SSc-related RP, the results are contradictory, with one studying showing an improvement in patient-reported RP symptomology [66] and the other showing no significant difference, including digital artery resistance after a cold challenge [67].…”

Section: Sympatholytic Drugs 4421 A-1 Adrenergic Receptor Antagonistsmentioning

confidence: 99%

Treatment options in Raynaud's phenomenon

Hughes

Herrick

2014

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

“…[26] The use of D-penicillamine as an antifibrotic agent in SSc is not supported by the results of a randomized trial that compared high to low doses of this drug [27]. Other medications and therapeutic procedures such as cyclosporine A [28][29][30][31], sirolimus, tacrolimus [32], antithymocyte globulin [33,34], prazosin [35,36], and ketanserin [37][38][39][40][41][42] have also been used as a therapy for SSc without achieving solid evidence of benefits. Nevertheless, we note that the mechanisms of action observed in conventional treatments are in several cases common also to newer molecules, as illustrated in Table 2.…”

Section: Conventional Treatments For Sscmentioning

confidence: 99%

Recent Advances in the Treatment of Systemic Sclerosis

Bournia

Vlachoyiannopoulos

Selmi

et al. 2009

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by widespread vascular injury and progressive fibrosis of the skin and internal organs. The involvement of internal organs results in significant morbidity and mortality of SSc patients with cardiopulmonary involvement being the leading cause of SSc-related deaths. The management of SSc patients remains a challenge because therapeutic options are rather limited and no therapy has definitively shown a disease-modifying effect. A significant progress that has recently been made in the understanding of the SSc pathogenesis contributed to the introduction of new therapeutic options. Preliminary clinical studies have yielded promising results for mycophenolate mofetil, anti-CD20 antibodies, and stem-cell in the treatment of SSc. Multicenter cohort studies help understand the natural history of SSc, which leads to improvement in the care of SSc patients. The major objective of those studies is to establish the screening strategies for early diagnosis and, subsequently, to introduce appropriate management concerning specific organ involvement in SSc as well as to formulate specific treatment recommendations.

show abstract

A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma

Cited by 15 publications

References 0 publications

MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial

MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial

Treatment options in Raynaud's phenomenon

Recent Advances in the Treatment of Systemic Sclerosis

Contact Info

Product

Resources

About